Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis
Carcinoma, Renal Cell
Receptor Protein-Tyrosine Kinases
Two courses of postorchiectomy adjuvant chemotherapy were safe and well tolerated and markedly decreased the relapse rate in high-risk patients with clinical Stage I nonseminomatous germ cell testicular tumor without additional surgery or more protracted chemotherapy. This approach may avoid potential problems with compliance and diminish the cost of scrupulous follow-up. Our results support that surveillance for carefully selected patients at a low risk of relapse is appropriate.